A huge leap in fine for wrongly using mobility parks, help with childcare costs and access to Keytruda are just some of the ...

Ten years on from their approval, GlobalData reviews their market entry strategies, pricing dynamics over time, and ...

We recently published a list of 10 Best Major Stocks to Invest In According to Analysts. In this article, we are going to ...

We recently published a list of 10 Best Healthcare Stocks To Buy According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other ...

It is the first of a slew of cancer drugs to now funded by Pharmac following the agency's multi-million dollar budget boost.

And 1 October means families can claim the new childcare payment FamilyBoost that we announced in the Budget. This gives eligible parents a refund of 25 per cent of the Early Childhood Education (ECE) ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.

Merck follows in the footsteps of Bristol Myers Squibb, which in December 2023 also failed to secure a late-stage victory for ...

Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of ...

Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...

Merck said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial ...